JPH02108A - 眼圧降下剤 - Google Patents

眼圧降下剤

Info

Publication number
JPH02108A
JPH02108A JP63230469A JP23046988A JPH02108A JP H02108 A JPH02108 A JP H02108A JP 63230469 A JP63230469 A JP 63230469A JP 23046988 A JP23046988 A JP 23046988A JP H02108 A JPH02108 A JP H02108A
Authority
JP
Japan
Prior art keywords
dihydro
keto
ethyl
pgs
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP63230469A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0571567B2 (2
Inventor
Ryuzo Ueno
隆三 上野
Takashi Ueno
隆司 上野
Tomio Oda
小田　冨雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ueno Seiyaku Oyo Kenkyujo KK
Original Assignee
Ueno Seiyaku Oyo Kenkyujo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26532381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH02108(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ueno Seiyaku Oyo Kenkyujo KK filed Critical Ueno Seiyaku Oyo Kenkyujo KK
Priority to JP63230469A priority Critical patent/JPH02108A/ja
Publication of JPH02108A publication Critical patent/JPH02108A/ja
Publication of JPH0571567B2 publication Critical patent/JPH0571567B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP63230469A 1987-09-18 1988-09-14 眼圧降下剤 Granted JPH02108A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP63230469A JPH02108A (ja) 1987-09-18 1988-09-14 眼圧降下剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP62-235890 1987-09-18
JP23589087 1987-09-18
JP62-334037 1987-12-29
JP33403787 1987-12-29
JP63230469A JPH02108A (ja) 1987-09-18 1988-09-14 眼圧降下剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP5024099A Division JP2592204B2 (ja) 1987-09-18 1993-02-12 眼圧降下剤

Publications (2)

Publication Number Publication Date
JPH02108A true JPH02108A (ja) 1990-01-05
JPH0571567B2 JPH0571567B2 (2) 1993-10-07

Family

ID=26532381

Family Applications (2)

Application Number Title Priority Date Filing Date
JP63230469A Granted JPH02108A (ja) 1987-09-18 1988-09-14 眼圧降下剤
JP5024099A Expired - Lifetime JP2592204B2 (ja) 1987-09-18 1993-02-12 眼圧降下剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP5024099A Expired - Lifetime JP2592204B2 (ja) 1987-09-18 1993-02-12 眼圧降下剤

Country Status (11)

Country Link
US (1) US5001153A (2)
EP (2) EP0455264B1 (2)
JP (2) JPH02108A (2)
KR (1) KR930000051B1 (2)
AT (2) ATE82499T1 (2)
CA (1) CA1328075C (2)
DE (2) DE3850676T2 (2)
ES (1) ES2052735T3 (2)
GB (1) GB2209939B (2)
GR (1) GR3006319T3 (2)
NZ (1) NZ226197A (2)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013869A1 (fr) * 1990-03-08 1991-09-19 Shionogi & Co., Ltd. Derive de 15-desoxyprostaglandine
JPH04253913A (ja) * 1990-05-22 1992-09-09 Aarutetsuku Ueno:Kk 眼科用医薬組成物
JPH04253910A (ja) * 1990-05-22 1992-09-09 Aarutetsuku Ueno:Kk 点眼用組成物
JPH04253912A (ja) * 1990-05-22 1992-09-09 Aarutetsuku Ueno:Kk 眼科用医薬組成物
JPH04253911A (ja) * 1990-05-22 1992-09-09 Aarutetsuku Ueno:Kk 眼科用組成物
JPH0565227A (ja) * 1991-03-01 1993-03-19 Ueno Seiyaku Oyo Kenkyusho:Kk 医薬組成物
WO1994029300A1 (fr) * 1993-06-07 1994-12-22 Rhone Poulenc Agrochimie Fongicides pyrazoles substitues en position 3 par un heterocycle
JPH08109132A (ja) * 1988-09-06 1996-04-30 Pharmacia Ab プロスタグランジン誘導体を含有する緑内障または眼圧亢進の局所治療のための眼科用組成物
JPH10120572A (ja) * 1993-12-15 1998-05-12 Alcon Lab Inc 局所的眼薬組成物及びそのためのプロスタグランジン化合物
WO2000038689A1 (en) * 1998-12-25 2000-07-06 Sucampo, A.G. Drug compositions for the treatment of ocular hypertension or glaucoma
JP2002104970A (ja) * 2000-08-25 2002-04-10 Sucampo Ag 眼科手術において眼圧を制御するための組成物
JP2003527430A (ja) * 2000-03-24 2003-09-16 スカンポ・アクチェンゲゼルシャフト １５−ケトプロスタグランジンまたはその誘導体を含むアポトーシス抑制剤
WO2004019951A1 (ja) 2002-08-29 2004-03-11 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
WO2005044276A1 (ja) * 2003-11-07 2005-05-19 Senju Pharmaceutical Co., Ltd. プロスタグランジン含有医薬組成物
JP2007211011A (ja) * 2006-02-07 2007-08-23 R Tec Ueno:Kk １５−ケトプロスタグランジンｅ誘導体の製造法
WO2007105691A1 (ja) * 2006-03-13 2007-09-20 R-Tech Ueno, Ltd. 水性組成物
WO2012105674A1 (ja) 2011-02-04 2012-08-09 興和株式会社 緑内障予防又は治療のための薬物療法
WO2016063184A1 (en) 2014-10-20 2016-04-28 Sentiss Pharma Private Limited Ophthalmic solution

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5236907A (en) * 1988-10-01 1993-08-17 R-Tech Ueno Ltd. Ocular hypotensive agents
US6420422B1 (en) 1987-09-18 2002-07-16 Sucampo Pharmaceuticals, Inc. Ocular hypotensive agents
JP2597629B2 (ja) 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
EP1300149A3 (en) * 1988-09-06 2003-05-14 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6187813B1 (en) 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
DE68928551T2 (de) * 1988-10-01 1998-04-23 Ueno Seiyaku Oyo Kenkyujo Kk Oculare hypotensive Mittel
US5234954A (en) * 1989-07-27 1993-08-10 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
EP0410652B1 (en) * 1989-07-27 1995-05-17 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Use of 15-keto-prostanoic acid derivatives in the manufacture of a medicament for improvement of excretion of potassium ion
ATE121624T1 (de) * 1989-08-09 1995-05-15 Ueno Seiyaku Oyo Kenkyujo Kk Verwendung von prostansäurederivaten zur herstellung von arzneimitteln zur verbesserung der ausscheidung von nichtprotein in die därme.
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
US5256696A (en) * 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
TW224942B (2) * 1990-04-04 1994-06-11 Adka Ueno Kk
ATE174221T1 (de) * 1990-05-01 1998-12-15 R Tech Ueno Ltd Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
US5175189A (en) * 1990-05-22 1992-12-29 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of ocular hypertension with a synergistic combination for ophthalmic use
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
US5270049A (en) * 1990-11-09 1993-12-14 Allergan, Inc. 2-decarboxyl-2-aminoalkyl-prostaglandins as ocular hypotensives
US5139491A (en) * 1990-12-06 1992-08-18 Allergan, Inc. 2-decarboxyl-2-alkoxyalkyl prostaglandins as ocular hypotensives
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
CA2065889C (en) * 1991-10-02 2002-08-27 Tetsuya Sugiyama Increasing the choroidal blood flow
EP0668076B1 (en) * 1992-08-26 2002-09-04 Sucampo AG Stabilization of a prostanoic acid compound
US6184250B1 (en) 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5387608A (en) * 1993-08-17 1995-02-07 Allergan, Inc. Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl sulfonamidomethyl and derivatives thereof as therapeutic agents
US5807892A (en) * 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
TW420611B (en) * 1995-03-10 2001-02-01 R Tech Ueno Ltd Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder
AU7680096A (en) * 1995-12-22 1997-07-17 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
CN1237157A (zh) 1996-11-12 1999-12-01 阿尔康实验室公司 作为眼压降低剂的前列腺素的顺式－△4类似物
US6680339B2 (en) 1996-11-12 2004-01-20 Alcon Manufacturing, Ltd. 15-fluoro prostaglandins as ocular hypotensives
DE69705421T2 (de) * 1996-11-12 2002-05-16 Alcon Laboratories, Inc. 15-fluoro-prostaglandine als augendrucksenkende mittel
ATE266397T1 (de) 1997-02-04 2004-05-15 Murray A Johnstone Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
EP0968183A2 (en) 1997-03-07 2000-01-05 Alcon Laboratories, Inc. 13-thia prostaglandins for use in glaucoma therapy
US6770675B2 (en) 1997-03-17 2004-08-03 Novartis Ag Compositions and methods for reducing ocular hypertension
ATE326972T1 (de) 1997-10-13 2006-06-15 R Tech Ueno Ltd Heilende zusammensetzung für intraokulare hypertension oder glaukom
US6156785A (en) * 1998-01-23 2000-12-05 Merck Sharp & Dohme B.V. Method for increasing oxygen tension in the optic nerve and retina
US6096783A (en) * 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
SE9900672D0 (sv) 1999-02-25 1999-02-25 Synphora Ab Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
TWI225398B (en) 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
US6576663B2 (en) 1999-12-22 2003-06-10 Alcon, Inc. 6-Keto prostaglandin F1α and analogs for treating dry eye
US6548535B2 (en) * 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
AU771130B2 (en) * 2000-01-18 2004-03-11 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CA2402597C (en) * 2000-03-16 2011-04-26 Sucampo Ag Composition for use in treatment of ocular hypertension and glaucoma
US6458836B1 (en) 2000-03-16 2002-10-01 Sucampo, A.G. Treatment of ocular hypertension and glaucoma
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US20020035148A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension
CA2422031C (en) * 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
US6291522B1 (en) * 2000-09-27 2001-09-18 Allergan Sales, Inc. Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
EP1487438A4 (en) * 2002-03-15 2007-08-15 Merck & Co Inc COMPOSITIONS AND METHODS FOR TREATING GLUCKOM AND OKULAR HYPERTENSION
WO2003103664A1 (en) * 2002-06-06 2003-12-18 Merck Frosst Canada & Co. 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
US20050256117A1 (en) * 2002-06-14 2005-11-17 Meng Hsin Chen Ophthalmic compositions for treating ocular hypertension
EP1515730A4 (en) * 2002-06-17 2005-07-20 Merck & Co Inc NEW MAXI-K CHANNEL BLOCKS, USE METHOD AND METHOD FOR THE PRODUCTION THEREOF
WO2003105724A2 (en) * 2002-06-17 2003-12-24 Merck & Co., Inc. Novel maxi-k channel blockers, methods of use and process for making the same
JP2005532361A (ja) * 2002-06-17 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症の治療用の眼科用組成物
US8580851B2 (en) * 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
AU2003258433A1 (en) * 2002-08-28 2004-03-19 Merck Frosst Canada Ltd Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
US20060167081A1 (en) * 2002-10-25 2006-07-27 Xavier Billot Ep4 receptor agonists
US7972612B2 (en) 2002-11-18 2011-07-05 Santen Pharmaceutical Co., Ltd. Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker
US7414067B2 (en) * 2003-03-27 2008-08-19 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
WO2005011704A1 (ja) * 2003-07-31 2005-02-10 Santen Pharmaceutical Co., Ltd. プロスタグランジン含有製品
TWI495471B (zh) * 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
CN102526064A (zh) * 2004-12-09 2012-07-04 参天制药株式会社 含有分子内具有氟原子的前列腺素的制品
WO2006068266A1 (ja) * 2004-12-24 2006-06-29 Santen Pharmaceutical Co., Ltd. プロスタグランジンＦ２ａ誘導体含有製品
EP1830793A1 (en) * 2004-12-29 2007-09-12 R-Tech Ueno, Ltd. Composition and method for scalp and hair treatment
KR20160120809A (ko) * 2005-03-04 2016-10-18 수캄포 아게 말초 혈관 질환 치료를 위한 방법 및 조성물
US20090018204A1 (en) * 2007-07-13 2009-01-15 Brinkenhoff Michael C Composition and method for enhancing hair growth
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
MY150518A (en) 2008-04-24 2014-01-30 Allergan Inc Substituted gamma lactams as therapeutic agents
WO2009132085A1 (en) * 2008-04-24 2009-10-29 Allergan, Inc. Substituted arylcyclopentenes as prostaglandin ep2 agonists
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US8609729B2 (en) 2009-04-15 2013-12-17 Sucampo Ag Method for treating macular degeneration
PH12012500928A1 (en) 2009-11-09 2012-11-26 Allergan Inc Compositions and methods for stimulating hair growth
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
AU2010358560B2 (en) 2010-08-02 2015-02-12 Ac Patent Holding Inc. Composition, method and kit for enhancing hair
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
TW201247206A (en) 2011-04-07 2012-12-01 Sucampo Ag Method for treating asthenopia
US8592483B2 (en) * 2011-08-05 2013-11-26 Sucampo Ag Method for treating schizophrenia
AR092821A1 (es) 2012-04-20 2015-05-06 Sucampo Ag Conjugado de derivado de acido graso-polimero

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1476661A (en) * 1974-05-13 1977-06-16 American Cyanamid Co Prostaglandins
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3785602T2 (de) * 1986-03-13 1993-09-02 Univ Columbia Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augen-hypertension und glaukom.
US4824857A (en) * 1986-05-16 1989-04-25 Yasumasa Goh Use of prostaglandin D2 -active substances
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1323364C (en) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
DE3869471D1 (de) * 1987-05-15 1992-04-30 Ueno Seiyaku Oyo Kenkyujo Kk Fiebersteigende zusammensetzung.
JPS6453101A (en) * 1987-05-25 1989-03-01 Kurashiki Boseki Kk Equal tilt angle interference type film thickness gauge
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08109132A (ja) * 1988-09-06 1996-04-30 Pharmacia Ab プロスタグランジン誘導体を含有する緑内障または眼圧亢進の局所治療のための眼科用組成物
WO1991013869A1 (fr) * 1990-03-08 1991-09-19 Shionogi & Co., Ltd. Derive de 15-desoxyprostaglandine
JPH04253913A (ja) * 1990-05-22 1992-09-09 Aarutetsuku Ueno:Kk 眼科用医薬組成物
JPH04253910A (ja) * 1990-05-22 1992-09-09 Aarutetsuku Ueno:Kk 点眼用組成物
JPH04253912A (ja) * 1990-05-22 1992-09-09 Aarutetsuku Ueno:Kk 眼科用医薬組成物
JPH04253911A (ja) * 1990-05-22 1992-09-09 Aarutetsuku Ueno:Kk 眼科用組成物
JPH0565227A (ja) * 1991-03-01 1993-03-19 Ueno Seiyaku Oyo Kenkyusho:Kk 医薬組成物
WO1994029300A1 (fr) * 1993-06-07 1994-12-22 Rhone Poulenc Agrochimie Fongicides pyrazoles substitues en position 3 par un heterocycle
JPH10120572A (ja) * 1993-12-15 1998-05-12 Alcon Lab Inc 局所的眼薬組成物及びそのためのプロスタグランジン化合物
JP5011548B2 (ja) * 1998-12-25 2012-08-29 株式会社アールテック・ウエノ 高眼圧症あるいは緑内障の処置用医薬組成物
WO2000038689A1 (en) * 1998-12-25 2000-07-06 Sucampo, A.G. Drug compositions for the treatment of ocular hypertension or glaucoma
JP2003527430A (ja) * 2000-03-24 2003-09-16 スカンポ・アクチェンゲゼルシャフト １５−ケトプロスタグランジンまたはその誘導体を含むアポトーシス抑制剤
JP2002104970A (ja) * 2000-08-25 2002-04-10 Sucampo Ag 眼科手術において眼圧を制御するための組成物
JP2009298808A (ja) * 2002-08-29 2009-12-24 Santen Pharmaceut Co Ltd Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
WO2004019951A1 (ja) 2002-08-29 2004-03-11 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
WO2005044276A1 (ja) * 2003-11-07 2005-05-19 Senju Pharmaceutical Co., Ltd. プロスタグランジン含有医薬組成物
JP4762718B2 (ja) * 2003-11-07 2011-08-31 千寿製薬株式会社 プロスタグランジン含有医薬組成物
US8697751B2 (en) 2003-11-07 2014-04-15 Senju Pharmaceutical Co., Ltd. Pharmaceutical composition containing prostaglandin
JP2007211011A (ja) * 2006-02-07 2007-08-23 R Tec Ueno:Kk １５−ケトプロスタグランジンｅ誘導体の製造法
WO2007105691A1 (ja) * 2006-03-13 2007-09-20 R-Tech Ueno, Ltd. 水性組成物
WO2012105674A1 (ja) 2011-02-04 2012-08-09 興和株式会社 緑内障予防又は治療のための薬物療法
WO2016063184A1 (en) 2014-10-20 2016-04-28 Sentiss Pharma Private Limited Ophthalmic solution

Also Published As

Publication number Publication date
EP0455264B1 (en) 1994-07-13
ES2052735T3 (es) 1994-07-16
EP0308135A2 (en) 1989-03-22
GB2209939B (en) 1992-01-02
JP2592204B2 (ja) 1997-03-19
AU600168B2 (en) 1990-08-02
GB8821104D0 (en) 1988-10-05
DE3850676D1 (de) 1994-08-18
EP0455264A3 (en) 1991-11-27
KR930000051B1 (ko) 1993-01-06
CA1328075C (en) 1994-03-29
EP0455264A2 (en) 1991-11-06
DE3876050T2 (de) 1993-03-25
US5001153A (en) 1991-03-19
GR3006319T3 (2) 1993-06-21
ATE82499T1 (de) 1992-12-15
AU2231388A (en) 1989-03-23
DE3876050D1 (de) 1992-12-24
NZ226197A (en) 1992-02-25
GB2209939A (en) 1989-06-01
JPH0680571A (ja) 1994-03-22
DE3850676T2 (de) 1994-11-03
KR890004707A (ko) 1989-05-09
JPH0571567B2 (2) 1993-10-07
EP0308135B1 (en) 1992-11-19
EP0308135A3 (en) 1989-06-14
ATE108330T1 (de) 1994-07-15

Similar Documents

Publication Publication Date Title
JPH02108A (ja) 眼圧降下剤
US5151444A (en) Ocular hypotensive agents
US5194429A (en) Ocular hypotensive agents
US5166178A (en) Ocular hypotensive agents
EP0580268B1 (en) Ocular hypotensive agents
JP2597649B2 (ja) 気管・気管支拡張剤
JP2562239B2 (ja) 抗炎症剤
JP2001514628A (ja) 緑内障治療に用いるための１３−チアプロスタグランジン
KR920007570B1 (ko) 체온 상승제
JPH0798751B2 (ja) 点眼用組成物
US6956056B2 (en) Method for providing a cathartic effect
JP2511587B2 (ja) 眼科用医薬組成物
JP2511585B2 (ja) 眼科用組成物
US5236907A (en) Ocular hypotensive agents
US5212200A (en) Ocular hypotensive agents
JP2511586B2 (ja) 眼科用医薬組成物
US6420422B1 (en) Ocular hypotensive agents
JPH0296528A (ja) 眼圧降下剤
JPH0296529A (ja) 眼圧降下剤
DK176053B1 (da) Prostaglandinderivater til behandling af glaukom eller foröget okulært tryk
JPH0285248A (ja) １５―ケト―プロスタグランジンｅまたはｆ化合物からなる子宮収縮剤
GB2225573A (en) 13,14-dihydro-15-keto-PGFs
NZ226199A (en) 13,14-dihydro-15-keto-pgf derivatives and pharmaceutical compositions

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071007

Year of fee payment: 14

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081007

Year of fee payment: 15

EXPY Cancellation because of completion of term